Date: 2011-04-19
Type of information:
phase:
Announcement:
Company: The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) (Japan)
Product: influenza vaccine produced in EB66® cells
Action mechanism:
Disease: influenza
Therapeutic area: Infectious diseases
Country: Japan
Trial
details: Vivalis has announced that the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) initiated the first human injection of an investigational influenza vaccine produced in EB66® cells in Japan. This program is part of the codevelopment and license agreement signed between GlaxoSmithKline (GSK) Biologicals and Kaketsuken, to co-develop seasonal and pandemic influenza vaccines produced using Vivalis’ EB66® cell line.
This follows the first 2010 Investigational New Drug application (IND) granted to GSK Biologicals for human clinical studies by the U.S. FDA using the EB66® cell line for influenza vaccine production. The Kaketsuken trial is the second human clinical study in the world for EB66® produced materials.
Latest news:
